Envisagenics is a Cold Spring Harbor Lab spinout that identifies disease-specific splicing variants as therapeutic targets by integrating proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics. The company specializes in RNA splicing to find targets that others miss, and its first therapeutic program is in triple negative breast cancer. In only 8 months, using its SpliceCore® software platform, Envisagenics discovered a novel splicing isoform of a key signaling enzyme, which is present in 65% of TNBC patients, and designed an anti-sense oligonucleotide drug against this target. The drug is now being tested for efficacy in organoid and preclinical mouse models. Envisagenics also works with BioPharma customers to enhance their drug discovery efforts, and it recently closed an oncology deal with the Lung Cancer Initiative at Johnson & Johnson.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):